Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Inclusion Criteria: * Adequate performance status: * Breast - Karnofsky score \> 50; * Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score ≤2 * If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation. * Normal organ function within 14 days of study entry * Diagnosis of one of the following malignancies: * Metastatic breast cancer (BR) * Metastatic ovarian cancer (OV) * Metastatic endometrial cancer (EM) * Metastatic cervical cancer (CX) Breast Cancer Inclusion Criteria: * Measurable metastatic disease (\>1cm) in at least one site other than bone-only * Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease * Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen. Ovarian Cancer Inclusion Criteria: * Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) * Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma). * Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens. Endometrial Cancer Inclusion Criteria: * Measurable metastatic disease * Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens Cervical Cancer Inclusion Criteria: * Measurable metastatic disease * Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens. Exclusion Criteria: * Had/have the following prior/concurrent therapy: * Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed) * Investigational drugs/agents within 14 days of first dose of 852A * Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose) * Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions * Radiotherapy within 3 weeks of the first dose of 852A * Hematopoietic cell transplantation within 4 weeks of first dose of 852A * Evidence of active infection within 3 days of first dose of 852A * Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable) * Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication * History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk * Uncontrolled intercurrent or chronic illness * Active autoimmune disease requiring immunosuppressive therapy within 30 days * Active coagulation disorder not controlled with medication * Pregnant or lactating * Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated * Any history of brain metastases or any other active central nervous system (CNS) disease